ClinicalTrials.gg
Sign In
Status unknownNCT06752733AMPEAUpdated Dec 31, 2024

Cardiac Stunning After Electrical Cardioversion

An observational study in Atrial Fibrillation (AF), sponsored by Korea University Guro Hospital. Status unknown at 1 site in South Korea. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Korea University Guro Hospital · Observational

The sponsor has not verified this record recently (last verified Jan 2024), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this observational study is to evaluate cardiac stunning and electrocardiographic parameters through transthoracic echocardiography and 24 hours ECG conducted immediately following electrical cardioversion. The main question it aims to answer is:

Do echocardiographic and electrocardiographic parameters relating to cardiac stunning predict atrial fibrillation (AF) recurrence rates after electrical cardioversion?

Participants will undergo echocardiography and a 24-hour Holter monitoring immediately after electrical cardioversion.

02

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

03

In context

Atrial Fibrillation

3,957 studies on the registry are indexed under Atrial Fibrillation; 933 are open to participants now.

This study's planned enrollment of 160 is below the median of 300 across 1,390 observational studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Korea University Guro Hospital is the lead sponsor of 89 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Korea University College of Medicine, Guro Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with atrial fibrillation
  • Patients with persistent or symptomatic atrial fibrillation who are candidates for electrical cardioversion
  • Patients eligible for anticoagulation therapy for thromboembolism prevention before and after the procedure
  • Patients who can understand and provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age or over 80 years of age
  • Patients who do not consent to participate in the study
  • Patients with severe coronary artery stenosis
  • Patients with severe hepatic dysfunction
  • Patients with severe renal dysfunction
  • Patients with severe valvular heart disease
  • Patients with a high risk of severe bleeding
  • Patients with a history of atrial fibrillation-related catheter ablation or cardiac surgery
  • Patients with an expected life expectancy of less than 1 year
  • Potentially pregnant individuals
  • Patients deemed unsuitable for the study by the investigator
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • Atrial fibrillation

    A group of patients with atrial fibrillation refractory to pharmacological treatment who are candidates for electrical cardioversion

    Procedure: electrical cardioversion

Interventions

  • Procedureelectrical cardioversion

    synchronized electrical shocks to restore normal sinus rhythm in patients with atrial fibrillation, performed under sedation

06

What researchers measure

Primary outcomes

  1. The recurrence of atrial arrhythmia

    Time frame: From enrollment to the end of treatment at 12 months

07

Study locations

1 site
  • Korea University Medicine Guro hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06752733
Lead sponsor
Korea University Guro Hospital
Responsible party
Roh Seung Young (Professor, Korea University Guro Hospital) — Principal investigator
First posted
Dec 31, 2024
Start date
Feb 20, 2024
Primary completion
Aug 31, 2025 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Dec 31, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Atrial Fibrillation →

Other studies from this sponsor

Korea University Guro Hospital

Start the discussion